In addition, given the need for pharmacotherapy in about 10% of patients with critical limb ischaemia who have unreconstruturable disease and given that many of these patients have multiple problems, the number of contra-indications required to improve the safety of parenteral infusion Naftidrofuryl (200mg/ 10ml) would limit its therapeutic indications.